Polycystic ovary syndrome
- PMID: 27510637
- DOI: 10.1038/nrdp.2016.57
Polycystic ovary syndrome
Abstract
Polycystic ovary syndrome (PCOS) affects 5-20% of women of reproductive age worldwide. The condition is characterized by hyperandrogenism, ovulatory dysfunction and polycystic ovarian morphology (PCOM) - with excessive androgen production by the ovaries being a key feature of PCOS. Metabolic dysfunction characterized by insulin resistance and compensatory hyperinsulinaemia is evident in the vast majority of affected individuals. PCOS increases the risk for type 2 diabetes mellitus, gestational diabetes and other pregnancy-related complications, venous thromboembolism, cerebrovascular and cardiovascular events and endometrial cancer. PCOS is a diagnosis of exclusion, based primarily on the presence of hyperandrogenism, ovulatory dysfunction and PCOM. Treatment should be tailored to the complaints and needs of the patient and involves targeting metabolic abnormalities through lifestyle changes, medication and potentially surgery for the prevention and management of excess weight, androgen suppression and/or blockade, endometrial protection, reproductive therapy and the detection and treatment of psychological features. This Primer summarizes the current state of knowledge regarding the epidemiology, mechanisms and pathophysiology, diagnosis, screening and prevention, management and future investigational directions of the disorder.
Similar articles
-
Polycystic ovary syndrome and acne.Skin Therapy Lett. 2010 Nov-Dec;15(10):1-4. Skin Therapy Lett. 2010. PMID: 21076799
-
Current concepts of polycystic ovary syndrome.Baillieres Clin Obstet Gynaecol. 1997 Jun;11(2):307-33. doi: 10.1016/s0950-3552(97)80039-9. Baillieres Clin Obstet Gynaecol. 1997. PMID: 9536213 Review.
-
Polycystic ovary syndrome: a review for dermatologists: Part I. Diagnosis and manifestations.J Am Acad Dermatol. 2014 Nov;71(5):847.e1-847.e10; quiz 857-8. doi: 10.1016/j.jaad.2014.05.007. Epub 2014 Oct 15. J Am Acad Dermatol. 2014. PMID: 25437977 Review.
-
Polycystic Ovary Syndrome.Obstet Gynecol. 2018 Aug;132(2):321-336. doi: 10.1097/AOG.0000000000002698. Obstet Gynecol. 2018. PMID: 29995717 Review.
-
Polycystic ovary syndrome: a dermatologic approach.An Bras Dermatol. 2011 Jan-Feb;86(1):111-9. doi: 10.1590/s0365-05962011000100015. An Bras Dermatol. 2011. PMID: 21437531 Review. English, Portuguese.
Cited by
-
Serum levels of stem cell factor for predicting embryo quality.Sci Rep. 2024 May 22;14(1):11689. doi: 10.1038/s41598-024-61419-2. Sci Rep. 2024. PMID: 38778076 Free PMC article.
-
The microbial metabolite agmatine acts as an FXR agonist to promote polycystic ovary syndrome in female mice.Nat Metab. 2024 May;6(5):947-962. doi: 10.1038/s42255-024-01041-8. Epub 2024 May 20. Nat Metab. 2024. PMID: 38769396
-
Correlation between anti-mullerian hormone with insulin resistance in polycystic ovarian syndrome: a systematic review and meta-analysis.J Ovarian Res. 2024 May 18;17(1):106. doi: 10.1186/s13048-024-01436-x. J Ovarian Res. 2024. PMID: 38762718 Free PMC article.
-
Interlukin-22 improves ovarian function in polycystic ovary syndrome independent of metabolic regulation: a mouse-based experimental study.J Ovarian Res. 2024 May 11;17(1):100. doi: 10.1186/s13048-024-01428-x. J Ovarian Res. 2024. PMID: 38734641 Free PMC article.
-
Paxillin regulates androgen receptor expression associated with granulosa cell focal adhesions.Mol Hum Reprod. 2024 Apr 30;30(5):gaae018. doi: 10.1093/molehr/gaae018. Mol Hum Reprod. 2024. PMID: 38718206 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical